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Vitronectin Inhibits Neutrophil Apoptosis through
Activation of Integrin-Associated Signaling Pathways
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Cynthia B. Peterson5, David D. Chaplin2, and Edward Abraham6
1Departments of Medicine, 2Microbiology, and 3Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama; 4Department of
Anesthesiology and Pain Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea; 5Department of Biochemistry and
Cellular and Molecular Biology, University of Tennessee at Knoxville, Knoxville, Tennessee; and 6Wake Forest School of Medicine, Winston-Salem,
North Carolina
Vitronectin is present in large concentrations in serum and the extra-
cellular matrix. Although vitronectin is known to modulate neutrophil
adhesion and chemotaxis, and to contribute to neutrophil-associated
proinflammatory processes, a role in apoptosis has not been demon-
strated. In thepresent studies,we foundthatneutrophilsdemonstrated
more rapid progression to spontaneous or TNF-related apoptosis-
inducing ligand–induced apoptosis when incubated under vitronectin-
free conditions thanwhen vitronectinwas present. The ability of native
vitronectin to delay neutrophil apoptosis was not recapitulated by
the vitronectin somatomedin B domain. In contrast, inclusion of the
cyclo[Arg-Gly-Asp-D-Phe-Val] peptide in cultures containing vitro-
nectin resulted in enhanced neutrophil apoptosis, showing that the
vitronectin RGD motif (Arg-Gly-Asp motif) was responsible for the
antiapoptotic effects of vitronectin. Addition of antibodies to b1, b3,
or b5, but not to b2 or b4 integrins, reversed the ability of vitronectin
to diminish neutrophil apoptosis. The ability of vitronectin to en-
hance neutrophil viability was dependent on activation of phos-
phatidylinositol 3-kinase and extracellular signal–regulated kinase 1/2
kinases, but not on the p38 kinase. Increased numbers of apoptotic
neutrophils were present in the lungs of LPS-treated transgenic
vitronectin-deficient mice, as compared with control mice. These
results demonstrate a novel antiapoptotic function for vitronectin.
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Although neutrophils play a central role in host defense against in-
vading microbes, organ injury can result if neutrophils activated to
produce proinflammatory mediators remain in tissues for prolonged
periods. The timely progressionof neutrophils to apoptotic cell death
and subsequent clearance is essential for the successful resolution of
neutrophil-associated inflammatory processes (1). Under normal
conditions, neutrophils are short lived, but during inflammatory
responses, such as acute lung injury, they demonstrate prolonged
viability. The importance of diminished neutrophil apoptosis in
promoting tissue injury during inflammatory processes has been
demonstrated by studies in which pharmacologically induced in-
crease in apoptosis resulted in diminished severity of organ dysfunc-
tion, such as lung injury induced by LPS or hemorrhage (2–4).
Vitronectin is a glycoprotein present in large concentrations in
serum, extracellular matrix, and platelets, and participates in the
regulation of coagulation, fibrinolysis, and complement activation
(5, 6). Tissue levels of vitronectin markedly increase in pathophys-
iologic settings associated with acute inflammation, such as severe
sepsis, and appear to contribute to organ injury in such conditions
(7, 8). Vitronectin promotes neutrophil adhesion and migration
through interaction with integrins, including avb3, and other
ligands, such as the urokinase plasminogen activator (uPA) recep-
tor (uPAR) (9, 10). The first 43 amino acids of N-terminal–end
vitronectin consist of the somatomedin B (SMB) domain followed
by a short RGD motif (Arg-Gly-Asp) that is responsible for bind-
ing to integrins (45–47 aa). Integrins play an essential role in
many cellular processes, including cell survival, proliferation, mi-
gration, and matrix attachment. The vitronectin SMB domain has
been shown to bind plasminogen activator inhibitor (PAI) -1,
uPAR, collagen, and thrombin–antithrombin complexes. Previous
studies demonstrated that vitronectin and its binding partners,
PAI-1 and the uPA, can diminish the phagocytosis of apo-
ptotic cells by macrophages, a process referred to as efferocytosis
(11–13). However, a role for vitronectin in modulating neutrophil
apoptosis has not been described.
In the present studies, we found that vitronectin has potent
effects in diminishing spontaneous and extrinsically induced neu-
trophil apoptosis under in vitro and in vivo conditions. These
results demonstrate a novel antiapoptotic function for vitronectin
and provide a potential mechanism for the ability of vitronectin
to enhance neutrophil-associated proinflammatory responses.
MATERIALS AND METHODS
Mice
Vitronectin-deficient mice (B6.129S2(D2)-Vtntm1Dgi/J), as well as
control mice (C57BL/6J), were purchased from The Jackson Labo-
ratory (Bar Harbor, ME). Vitronectin knockout male mice were
crossed to B6D2F1/J female mice, and then backcrossed to C57BL/
6J for 12 generations before being interbred. Male mice (8–12 wk of
age) were used for experiments. All experiments were conducted
in accordance with institutional review board–approved protocols
(University of Alabama at Birmingham Institutional Animal Care
and Use Committee).
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CLINICAL RELEVANCE
These studies demonstrate a novel role for vitronectin
diminishing neutrophil apoptosis. Our experiments, showing
that exposure to vitronectin extends the lifespan of activated
neutrophils, provide new insights into the mechanisms un-
derlying acute lung injury. These studies also suggest that
therapeutic approaches that inhibit interaction between
vitronectin and activated neutrophils may be beneficial in
diminishing the severity of acute lung injury and other in-
flammatory processes in which neutrophils play a major role.
Reagents and Antibodies
Antibodies to total and phospho-(S473)Akt, phospho-(T202/Y204) extra-
cellular signal–regulated kinases (Erk)1/2, and phospho-(T180/Y182)p38,
as well as to induced myeloid leukemia cell differentiation protein Mcl-1
were purchased from Cell Signaling (Beverly, MA). Antibodies to b-actin
were from Sigma (St. Louis, MO). Propidium iodide and antibodies to
annexin V were purchased from EMD Chemicals (Gibbstown, NJ).
Mouse vitronectin was purchased from Abcam (Cambridge, MA). Vitro-
nectin SMB domain deletion mutant (vtn DSMB) vitronectin or vitronec-
tin SMB domain were expressed in Drosophila S2 cells using methods
described by Schar and colleagues (14), and proteins purified as de-
scribed by Thompson and colleagues (15). Mouse anti–integrin-b1,
-b2, b3, or -b4 antibodies and specific isotype control IgG were pur-
chased from BD Biosciences (San Diego, CA), whereas monoclonal
human anti–integrin-b5 (cross-reacting with mouse, clone KN52) was
purchased from eBioscience (San Diego, CA). RGDfv [cyclo(Arg-Gly-
Asp-D-Phe-Val)] and RADfv [cyclo(Arg-Ala-Asp-D-Phe-Val)] were
purchased from Enzo Life Science (Plymouth Meeting, PA). Recom-
binant mouse TNF-related apoptosis-inducing ligand (TRAIL)/tumor
necrosis factor ligand superfamily member 10 (TNFSF10) was obtained
from R&D Systems (Minneapolis, MN).
Neutrophil Isolation and Culture
Bonemarrowneutrophils were isolated usingmethods previously described
(16) and as described in the supplemental MATERIALS AND METHODS.
Measurement of Neutrophil Apoptosis
The percentage of early and late apoptotic cells was determined by
staining with annexin V–FITC and propidium iodide, followed by flow
cytometry (17) (see supplemental MATERIALS AND METHODS).
Western Blot Analysis
Western blot analysis was performed as previously described (16, 18)
(see supplemental MATERIALS AND METHODS).
Acute Lung Injury Model
Mice were treated with LPS (1 mg/kg) in saline or saline alone, admin-
istered intratracheally, in 50 ml saline, as previously described (16, 18)
(see supplemental MATERIALS AND METHODS).
Measurement of Neutrophil Apoptosis In Vivo
Infiltrating leukocytes were isolated from minced lung tissue by treatment
with collagenase-B (2 mg/ml; Roche) and DNase I (0.02 mg/ml; Sigma) in
Iscove’s modified Dulbecco’s medium supplemented with 1 mM sodium
pyruvate, 2 mM L-glutamine, 10 mg/ml penicillin–streptomycin, 25 mM
2-mercaptoethanol, and 0.1 mM nonessential amino acids (Life Technol-
ogies, Grand Island, NY) at 378C for 30 minutes. To determine the per-
centage of apoptotic neutrophils, the cells were incubated with annexin
V–FITC (Calbiochem, La Jolla, CA) and Gr1-PE (BD Bioscience) anti-
bodies and then analyzed by flow cytometry. Caspase-9 activity was mea-
sured in CD-11b–stained cells from bronchoalveolar lavage fluids using
standard fluorogenic substrates (Calbiochem).
Statistical Analyses
Statistical significance was determined by theWilcoxon rank sum test (inde-
pendent two-group Mann-Whitney U test) as well as Student’s t test for
comparisons between two groups. Multigroup comparisons were performed
using one-way ANOVA with Tukey’s post hoc test. A value of P less than
0.05 was considered significant. Analyses were performed on SPSS version
16.0 (IBM, Armonk, NY) for Windows (Microsoft Corp., Redmond, WA).
RESULTS
Vitronectin Increases Neutrophil Viability
In a first set of experiments, cell viability was measured in neutro-
phils isolated from the bonemarrow of vitronectin control (vtn1/1)
or vitronectin-deficient (vtn2/2) mice that were then incubated in
vitronectin-deficient or normal mouse serum. As shown in Figure
1A, neutrophils in each group (i.e., vtn2/2 neutrophils/vtn2/2 se-
rum or vtn1/1 neutrophils/vtn1/1 serum) had similar profiles of
viability (z90% viable) after culture for 24 hours. However, at 48
and 72 hours in culture, a marked increase in the percentage of
apoptotic cells was found among the vtn2/2 neutrophils incubated
in serum obtained from vtn2/2 mice as compared with vtn1/1 cells.
Although culture of neutrophils was initiated using the same num-
ber of cells, there was also a significant decrease in the total num-
ber of vtn2/2 cells compared with wild-type vtn1/1 neutrophils,
consistent with increased death of the vtn2/2 neutrophils.
Figure 1. Effects of vitronectin on neutrophil viability. (A)
Neutrophils obtained from the bone marrow of vitronectin
control (vtn1/1) mice were incubated with 5% serum from
vtn1/1 mice, and neutrophils obtained from the bone mar-
row of vitronectin-deficient (vtn2/2) mice were incubated
with 5% serum from vtn2/2 mice. Viable and apoptotic
neutrophils obtained at 0, 24, 48, or 72 hours after the
initiation of culture were identified by flow cytometry us-
ing staining with annexin V and propidium iodide (PI). The
percentage of viable neutrophils was determined by sub-
traction of PI and annexin V–positive cells from the total
population of cells. The numbers of neutrophils, calculated
after 0, 24, 48 or 72 hours of culture, are shown in the
right panel. Means (6SD) (n ¼ 4 independent sets of neu-
trophils to determine viable and apoptotic cells; n ¼ 3 to
determine number of cells) are shown. *P , 0.05 (P ¼
0.02), **P , 0.01 (P ¼ 0.006), ***P , 0.001 (P ¼
0.0002) compared with vtn1/1 cells. (B) Percentages of
viable and apoptotic neutrophils were determined among
vtn1/1 or vtn2/2 neutrophils after 48-hour incubation in
medium containing 5% vtn1/1 or vtn2/2 serum. Means
(6SD) (n ¼ 3 independent sets of neutrophils) are shown.
Left panel: **P, 0.01 (0.009) comparing vtn1/1 neutrophils
or **P , 0.01 (P ¼ 0.003) comparing vtn2/2 neutrophils
cultured in serum deficient or containing vitronectin. Right
panel: **P , 0.01 (P ¼ 0.0097) comparing vtn1/1 neutro-
phils or **P , 0.01 (P ¼ 0.002) comparing vtn2/2 neutro-
phils cultured in serum deficient or containing vitronectin.
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We next determined if vitronectin-dependent enhancement
of neutrophil viability was mediated by cellularly produced vitro-
nectin or vitronectin present in the serum that had been added to
the cultures. To examine this question, vtn1/1 or vtn2/2 bone
marrow neutrophils were incubated with serum obtained from
vtn2/2 or vtn1/1 mice. As shown in Figure 1B, the presence of
vitronectin in the culture medium, but not the vitronectin-
expressing status of the neutrophils, was responsible for the pres-
ervation of neutrophil viability. In particular, both vtn2/2 and
vtn1/1 neutrophils were more susceptible to apoptosis when cul-
tured in vtn2/2 serum than when exposed to vtn1/1 serum. Sim-
ilarly, inclusion of vitronectin-containing serum in the cell cultures
increased the percentage of viable vtn1/1 and vtn2/2 neutrophils.
Additional experiments confirmed that vitronectin dose-
dependently decreased apoptosis among vtn2/2 neutrophils (Fig-
ure 2A). Similarly, the percentage of apoptotic neutrophils was
diminished in a dose-dependent manner by inclusion of purified
vitronectin in the cultures (Figure 2B). As shown in Figure E1 in
the online supplement, exposure of mature neutrophils isolated
from peritoneal exudates to vitronectin also diminished progres-
sion to apoptosis. In particular, we found increased apoptosis and
diminished numbers of viable cells over time in cultures of vtn2/2
as compared with wild-type (vtn1/1) peritoneal neutrophils. Con-
sistent with these results, culture of peritoneal neutrophils (vtn2/2)
with serum containing vitronectin resulted in decreased percen-
tages of apoptotic cells (Figure E1B).
Exposure of bone marrow neutrophils to vitronectin dimin-
ished activation of caspase 9 and caspase 3 (Figure 2C). Of note,
the antiapoptotic effect of vitronectin was not limited to spon-
taneous death among neutrophils, but also diminished extrinsic
apoptotic death induced through the TRAIL/tumor necrosis
factor receptor type 1–associated DEATH domain protein
(TRADD) signaling pathway (Figure 2D).
The Antiapoptotic Effects of Vitronectin Are Dependent
on the RGD Domain
The SMB domain and RGDmotifs of vitronectin have previously
been shown to modulate cellular viability in nonmyeloid cell pop-
ulations (19–26). To determine the importance of SMB domain in
affecting neutrophil viability and apoptosis, vtn2/2 bone marrow
neutrophils were incubated with purified SMB domain or
recombinant vitronectin that lacked the SMB domain (i.e., vtn
Figure 2. Effects of vitronectin on spontaneous or TNF-related apoptosis-
inducing ligand (TRAIL)–induced neutrophil apoptosis. (A) Vtn2/2 neutrophils
were cultured with vtn2/2 serum or medium that was dose-dependently
supplemented with serum from vtn1/1 mice. Means (6SD) (n ¼ 4 indepen-
dent sets of neutrophils) are shown. *P, 0.05 (P¼ 0.025), ***P, 0.001 (P¼
0.0006). (B) Vtn2/2 neutrophils were treated with purified vitronectin at the
indicated concentrations for 30 minutes. Cells were then cultured in
media containing 5% serum from vtn2/2 mice for 48 hours and the percen-
tages of apoptotic cells determined by flow cytometry. Means (6SD) (n ¼ 3
independent sets of neutrophils) are shown. ***P , 0.001 (P ¼ 0.0002)
compared with untreated cells. (C) vtn1/1 or vtn2/2 neutrophils were treated
with purified vitronectin (0 or 100 nM) for 30minutes, then cultured inmedia
containing 5% serum from vtn2/2 mice for 48 hours, followed by measure-
ment of the activity of caspase 9 and caspase 3. Means (6SD) (n ¼ 3
independent sets of neutrophils). **P , 0.01 (P ¼ 0.002), ***P ,
0.001 (P ¼ 0.0006) compared with vtn1/1 cells, or #P , 0.05 (P ¼
0.03), ##P , 0.01 (P ¼ 0.002) compared with vtn2/2 untreated cells.
(D) The percentage of apoptotic cells was determined after exposure of
neutrophils to purified vitronectin (0 or 100 nM) for 4 hours, followed by
inclusion of TRAIL (0 or 30 ng/ml) for an additional 44 hours. Means
(6SD) (n ¼ 3 independent sets of neutrophils) are shown. ***P , 0.001
(P ¼ 0.0002) compared with untreated cells or ###P , 0.001 (P ¼
0.0002) compared with cells treated with TRAIL alone.
Figure 3. The RGD motif is required for the antiapoptotic effect of vitro-
nectin. vtn2/2 neutrophils were cultured with (A) vitronectin lacking the
somatomedin B (SMB) domain (DSMB domain), or (B) wild-type vitro-
nectin (0 or 100 nM) or purified SMB domain (0–300 nM) for 30 minutes.
Cells were cultured in 5% serum from vtn2/2 mice for 48 hours and the
percentage of apoptotic neutrophils determined. vtn2/2 neutrophils were
treated with (C) RGDfv [cyclo(Arg-Gly-Asp-D-Phe-Val)] (0, 0.3, or 1 mM)
or (D) RGDfv (0 or 1 mM) or RADfv [cyclo(Arg-Ala-Asp-D-Phe-Val)] (0 or
1 mM) for 30 minutes before exposure to vitronectin. The percentages of
apoptotic and viable cells were determined by flow cytometry after 48
hours of culture. Means (6SD) (n¼ 3 independent sets of neutrophils) are
shown. (A) ***P , 0.001 (P ¼ 0.0002); (B) ***P , 0.001 (P ¼ 0.002); (C)
***P, 0.001 (P ¼ 0.0002), **P, 0.01 (P ¼ 0.006); and (D) ***P, 0.001
(P ¼ 0.0002) compared with untreated cells.
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DSMB). In a manner similar to wild-type vitronectin (Figure 2B),
vtn DSMB dose-dependently diminished neutrophil apoptosis
(Figure 3A). To confirm that the SMB domain was not respon-
sible for the antiapoptotic effects of vitronectin, we cultured neu-
trophils with purified SMB domain and found no effects on the
percentage of apoptotic neutrophils, unlike the reduction in neu-
trophil apoptosis induced by incubation with wild-type vitronec-
tin (Figure 3B). Of note, the effects of recombinant vitronectin
proteins were not due to potential contamination with LPS. As
shown in Figures E2A and E2B, inclusion of polymyxin B in
the cell cultures did not modify the effects of vitronectin DSMB
or the vitronectin SMB domain on neutrophil apoptosis.
We next determined whether the RGDmotif is responsible for
the effects of vitronectin on neutrophil viability. To examine this
possibility, we used the RGD-blocking peptide, RGDfv, and com-
pared its effects on neutrophil apoptosis with RADfv, a structur-
ally similar analog that is unable to interact with the RGD motif
(27). As shown in Figures 3C and 3D, inclusion of RGDfv in the
cultures dose-dependently diminished the effects of vitronectin
on neutrophil viability, but exposure to RADfv had no effect
when compared with treatment of the cells with vitronectin alone.
Taken together, these results show that the antiapoptotic effect
of vitronectin is mediated by the RGD motif, but not the SMB
domain.
Interactions between Vitronectin and Integrins Result
in Diminished Neutrophil Apoptosis
Previous studies have shown that the vitronectinRGDmotif binds
avb1, avb3, and avb5 integrins (28). Given that blockade of the
vitronectin RGD domain with RGDfv diminished the antiapop-
totic effects of vitronectin, suggesting that RGD-binding integrins
were responsible for the properties of vitronectin on neutrophil
viability, we examined the effect of specific antibodies to b1, b2,
b3, b4, or b5 integrins on vitronectin-induced decrease in sponta-
neous neutrophil apoptosis. As shown in Figure 4A, antibodies to
Figure 4. Interactions between integrins and
vitronectin modulate neutrophil survival.
(A–E) vtn2/2 neutrophils were cultured with
antibodies (1 mg/ml) to b1, b2, b3, b4, or b5
integrins or isotype-specific IgG (1 mg/ml)
for 30 minutes. The cells were then washed
and incubated with purified vitronectin (0 or
100 nM) for 30 minutes, followed by culture
with media containing 5% serum from
vtn2/2 mice for 48 hours. Means (6SD) (n ¼
3 independent sets of neutrophils) are shown.
(A) ***P , 0.001 (P ¼ 0.0002); (B) **P , 0.01
(P ¼ 0.003), ***P , 0.001 (P ¼ 0.0005); (C)
***P , 0.001 (P ¼ 0.0002); (D) ***P , 0.001
(P ¼ 0.0002 and 0.0003); and (E) ***P ,
0.001 (P ¼ 0.0002) compared with untreated
control cells (con).
Figure 5. Effects of vitronectin on kinase acti-
vation. vtn2/2 neutrophils were cultured with
purified mouse vitronectin (0 or 100 nM) for 4
or 8 hours. (A) Representative Western blots
show the levels of total and phosphorylated
protein kinase B (Akt) and extracellular signal–
regulated kinases (Erk)1/2 after incubation of
neutrophils with or without vitronectin for 0,
4, or 8 hours, whereas (B) shows the
amounts of total and phospho-p38 and lev-
els of induced myeloid leukemia cell differ-
entiation protein (Mcl-1) obtained from
neutrophils cultured with vitronectin (0 or
100 nM) for 8 hours. Similar results were
obtained from a second independent ex-
periment. (C) The percentage of apoptotic neutrophils was determined after culture for 48 hours with LY294002 (LY; 0 or 10 mM), PD98059
(PD; 0 or 50 mM), or SB203580 (SB; 0 or 10 mM) and purified mouse vitronectin (0 or 100 nM) for 48 hours. Means (6SD) (n ¼ 3 independent sets
of neutrophils) are shown. ***P , 0.001 (from left to right: P ¼ 0.0003, 0.0003, 0.0002, and 0.0007) compared with untreated cells; ###P , 0.001
(P ¼ 0.0003) compared with cells treated with SB203580 alone. NS, not significant.
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b1, b3, or b5, but not b2 or b4, integrins diminished vitronectin-
dependent increases in neutrophil viability. These results indicate
that vitronectin enhances viability of neutrophils through inter-
action with specific integrins, particularly b1, b3, and b5.
Involvement of Phosphatidylinositol 3-Kinases and Erk in
Vitronectin-Induced Enhancement of Neutrophil Viability
Treatment of bone marrow neutrophils with vitronectin resulted
in enhanced phosphorylation of Akt and Erk1/2, but not of p38
mitogen-activated protein kinase, and increased expression of
the antiapoptotic protein, Mcl-1 (Figures 5A and 5B). To estab-
lish which of these kinases might be involved in mediating the
antiapoptotic effects of vitronectin, neutrophils were cultured
with combinations of vitronectin and specific inhibitors of
phosphatidylinositol 3-kinases (PI3-K) (LY294002), Erk1/2
(PD98059), or p38 (SB203580). Inhibition of PI3-K, Erk1/2, or
p38 resulted in increased apoptosis of neutrophils, as previously
reported (29). Inclusion of vitronectin in the cultures did not
affect the increase in neutrophil apoptosis induced by PI3-K or
Erk1/2 inhibitors, but did reduce the enhanced rate of apoptosis
found after p38 inhibition (Figure 5C). These results implicate
the activation of PI3-K/Akt and Erk1/2 in mediating the anti-
apoptotic effects of vitronectin in neutrophils.
Vitronectin Is Associated with Prolonged Longevity
of Neutrophils during LPS-Induced Acute Lung Injury
Given our results showing that vitronectin has potent antiapoptotic
effects in cultured neutrophils, we next determined if vitronectin
has similar effects in vivo. To examine this question, acute lung
injury was induced in control (vtn1/1) and vtn2/2 mice by intra-
tracheal administration of LPS, and then the percentage of apo-
ptotic neutrophils in the lung interstitium determined 24 hours
after LPS exposure, the time of peak inflammatory response. As
shown in Figure 6A, the percentage of apoptotic neutrophils pres-
ent in the lungs was significantly increased in vtn2/2 as compared
with vtn1/1 mice. Similar to the results obtained from flow cytom-
etry using staining with annexin V, increased activity of caspase 9
and decreased numbers of neutrophils were found in the lungs of
vtn2/2 as compared with vtn1/1 mice during acute lung injury
(Figures 6B and 6C). These in vivo findings are similar to those
Figure 6. Vitronectin deficiency is associated with
enhanced neutrophil apoptosis in the lungs of mice
with LPS-induced acute lung injury. (A) Number of
apoptotic neutrophils (annexin V/GR1-FITC) ob-
tained from the lungs of vtn1/1 or vtn2/2 mice
24 hours after LPS (1 mg/kg, intratracheally) ad-
ministration. Means (6SD) (n ¼ 4 mice in each
group). *P , 0.05 (P ¼ 0.02) compared with
vtn1/1. (B and C) Total white cell and neutrophil
numbers, and caspase 9 activity in neutrophils ob-
tained from bronchoalveolar lavage 24 hours after
LPS administration to vtn1/1 or vtn2/2 mice. (B)
Means (6SD) (n ¼ 4 mice in each group). *P ,
0.05 (P ¼ 0.02) compared with vtn1/1. (C) Results
obtained from three mice per group. P , 0.1 com-
pared with vtn1/1.
Figure 7. Vitronectin-dependent activation of integrin sig-
naling pathways inhibits neutrophil apoptosis. Interactions
between the vitronectin RGD motif and integrins induce
activation of Akt and Erk1/2, inhibiting both spontaneous
and extrinsically induced apoptosis in neutrophils. MAPK,
mitogen-activated protein kinase; TRADD, tumor necrosis
factor receptor type 1–associated DEATH domain protein.
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showing that addition of vitronectin to neutrophils cultured with
LPS resulted in diminished levels of apoptosis (Figure E3).
DISCUSSION
In the present experiments, we found that vitronectin has potent
regulatory effects on neutrophil viability (Figure 7). In particular,
exposure to vitronectin under both in vitro and in vivo conditions
was associated with reduced apoptosis in neutrophils. The anti-
apoptotic properties of vitronectin were dependent on the RGD,
but not the SMB domain, consistent with interactions between
RGD-binding integrins and vitronectin being responsible for the
effects on neutrophil viability. Blocking experiments demon-
strated that the antiapoptotic actions of vitronectin were due to
interactions with b1, b3, and b5, but not b2 or b4 integrins, con-
firming that the mechanism through which vitronectin enhances
viability of neutrophils is by interaction with specific integrins,
particularly those that include the b1, b3, or b5 subunits, consis-
tent with well described interactions between vitronectin and
these integrin subunits (30). Such results are also concordant with
previously reported findings in nonmyeloid cell populations, in-
cluding microvascular endothelial cells, human umbilical vein
endothelial cells, and human glioma cell lines, in which antiapop-
totic actions of vitronectin were mediated through interactions
with b3 and b5 integrins (31, 32).
Engagement of integrins has been shown to diminish neutrophil
apoptosis through activation of PI3-K/Akt and Erk1/2, generating
survival signals, including phosphorylation of Bcl-2–associated
death promoter (Bad) and Bcl-2–like protein 4 (Bax), followed
by dissociation of phosphorylated Bad and Bax from Mcl-1 and
stabilization of intracellular levels of Mcl-1 (29, 33). Consistent
with the antiapoptotic effects of vitronectin arising from interac-
tions with integrins, the present experiments demonstrated that
culture of neutrophils with vitronectin increased activation of PI3-
K/Akt and Erk1/2, as well as increased levels of Mcl-1. Moreover,
pharmacologic inhibition of PI3-K or Erk1/2 abrogated the anti-
apoptotic effects of vitronectin.
The ability of vitronectin to diminish neutrophil apoptosis was
not limited in these studies to spontaneous cell death, but also
was present when apoptosis was induced through engagement of
death receptors by TRAIL. The mechanism by which vitronectin
diminishes the effects of TRAIL on neutrophil apoptosis may be
through activation of Akt, which has been shown to inhibit TRAIL
receptor–induced cell death (34, 35).
Under in vivo conditions, vitronectin, primarily through inter-
actions with its SMB domain, is often associated with proteins,
such as PAI-1 and the uPAR, that can affect apoptosis of neu-
trophils and other cell populations (9, 36). However, in the present
studies, purified vitronectin SMB domain had no effect on neu-
trophil apoptosis, whereas mutant vitronectin lacking the SMB
domain (vtn ΔSMB) still retained antiapoptotic activity, indicating
that the effects of vitronectin on neutrophil viability did not occur
through binding of secondary proteins to the SMB domain. The
RGD sequence of vitronectin is located adjacent to the SMB
domain (37, 38), and is included in the vtn ΔSMB mutant used
in these experiments. The ability of the RGD-blocking peptide,
RGDfv, to reverse the antiapoptotic effects of vitronectin strongly
suggests not only that the RGD domain of vitronectin is respon-
sible for such actions, but also that the effects of vitronectin on
neutrophil viability and apoptosis are directly due to interactions
between vitronectin itself and integrins, without involvement of
vitronectin-binding intermediary proteins.
After LPS-induced lung injury, there was a higher percentage
of apoptotic cells among the neutrophils infiltrating the lungs of
transgenic mice lacking vitronectin as compared with control
mice. These results are consistent with our in vitro experiments
showing that vitronectin decreases spontaneous or extrinsically
mediated apoptosis in cultured neutrophils, as well as in neu-
trophils stimulated with LPS. Of note, data analysis for Figure
6C performed with Mann-Whitney U test shows a P value of
0.1; however, a significant difference (P , 0.05) was obtained
using Student’s t test with the assumption that the variables are
normally distributed. Increased concentrations of vitronectin
are present in the alveoli and pulmonary interstitium of mice
with LPS-induced acute lung injury and in patients with the
acute respiratory distress syndrome (7, 8). In these settings,
large numbers of neutrophils activated to produce increased
amounts of proinflammatory mediators, including cytokines
and reactive oxygen species, accumulate in the airways and
parenchyma of the lungs (39, 40). Exposure of neutrophils that
migrate into the pulmonary interstitium and alveoli to high con-
centrations of vitronectin may result in diminished apoptosis
and prolonged presence in the lungs, thereby enhancing the
severity of tissue damage. Of note, diminished neutrophil apo-
ptosis is a well characterized finding during acute lung injury in
experimental models and in patients with this condition (39, 41,
42). Furthermore, in addition to its antiapoptotic effects, vitro-
nectin may also exacerbate the severity of acute lung injury
through decreasing the uptake and clearance of apoptotic neu-
trophils by alveolar and tissue-based macrophages (12), thereby
allowing the apoptotic neutrophils to progress to necrotic death
with associated release of proinflammatory contents into the
pulmonary parenchyma.
These experiments describe a novel antiapoptotic function
for vitronectin that may contribute to its role in neutrophil-
driven proinflammatory processes, such as acute lung injury. Be-
cause interactions between vitronectin and multiple integrins
appear to be responsible for its actions in delaying neutrophil
apoptosis, interventions specifically aimed at the RGD domain
of vitronectin may have greater efficacy in reversing the antia-
poptotic effects of vitronectin than would therapies directed
at blocking individual integrins. Future work will be necessary
to explore these issues.
Author disclosures are available with the text of this article at www.atsjournals.org.
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